# Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection

> **NCT03425994** · — · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 275 (actual)

## Conditions studied

- Chronic Hepatitis B in HIV Patient
- Kidney Injury
- Bone Diseases

## Interventions

- **DRUG:** Elvitegravir/Cobicistat/Emtricitabine

## Key facts

- **NCT ID:** NCT03425994
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-06
- **Primary completion:** 2019-02-22
- **Final completion:** 2019-10-11
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03425994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03425994, "Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03425994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*